News Releases

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The shareholders adopted the financial statements for the 2021 financial year (agenda item 2.e); approved the proposal to grant discharge to the members of the Board of

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022. The Company will hold an analyst conference call at 13.30 CET/07.30 EST today (12 May).

Pharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022. The Company will host a presentation for analysts at 13:30 CET/07:30 EST on 12 May 2022. Details for the presentation can be found below.  Conference call dial-in

An agreed Paediatric Investigation Plan (PIP) is the regulatory pathway to market authorization for leniolisib as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a

LEIDEN, Netherlands , April 1, 2022 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome

Pharming Group announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing

An agreed PIP is the regulatory pathway to market authorization for leniolisib as a treatment of activated phosphoinositide 3-kinase delta syndrome in children. Pharming announces that a positive decision has been made by the European Medicines Agency (EMA) on the Paediatric Investigation Plan